The global Communicable Diseases Drugs market was valued at US$ 28160 million in 2023 and is anticipated to reach US$ 68580 million by 2030, witnessing a CAGR of 6.6% during the forecast period 2024-2030.

Communicable Diseases Drugs Market

In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites

The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.

This report aims to provide a comprehensive presentation of the global market for Communicable Diseases Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Communicable Diseases Drugs.

Report Scope

The Communicable Diseases Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Communicable Diseases Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Communicable Diseases Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Communicable Diseases Drugs Market Report

Report Metric	Details
Report Name	Communicable Diseases Drugs Market
Accounted market size in 2023	US$ 28160 million
Forecasted market size in 2030	US$ 68580 million
CAGR	6.6%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	HIV Influenza TB Malaria Hepatitis HPV
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Communicable Diseases Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Communicable Diseases Drugs Market growing?

Ans: The Communicable Diseases Drugs Market witnessing a CAGR of 6.6% during the forecast period 2024-2030.

What is the Communicable Diseases Drugs Market size in 2030?

Ans: The Communicable Diseases Drugs Market size in 2030 will be US$ 68580 million.

Who are the main players in the Communicable Diseases Drugs Market report?

Ans: The main players in the Communicable Diseases Drugs Market are Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma

What are the Application segmentation covered in the Communicable Diseases Drugs Market report?

Ans: The Applications covered in the Communicable Diseases Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Communicable Diseases Drugs Market report?

Ans: The Types covered in the Communicable Diseases Drugs Market report are HIV, Influenza, TB, Malaria, Hepatitis, HPV

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Communicable Diseases Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 HIV

1.2.3 Influenza

1.2.4 TB

1.2.5 Malaria

1.2.6 Hepatitis

1.2.7 HPV

1.3 Market by Application

1.3.1 Global Communicable Diseases Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Communicable Diseases Drugs Market Perspective (2019-2030)

2.2 Communicable Diseases Drugs Growth Trends by Region

2.2.1 Global Communicable Diseases Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Communicable Diseases Drugs Historic Market Size by Region (2019-2024)

2.2.3 Communicable Diseases Drugs Forecasted Market Size by Region (2025-2030)

2.3 Communicable Diseases Drugs Market Dynamics

2.3.1 Communicable Diseases Drugs Industry Trends

2.3.2 Communicable Diseases Drugs Market Drivers

2.3.3 Communicable Diseases Drugs Market Challenges

2.3.4 Communicable Diseases Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Communicable Diseases Drugs Players by Revenue

3.1.1 Global Top Communicable Diseases Drugs Players by Revenue (2019-2024)

3.1.2 Global Communicable Diseases Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Communicable Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Communicable Diseases Drugs Revenue

3.4 Global Communicable Diseases Drugs Market Concentration Ratio

3.4.1 Global Communicable Diseases Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Communicable Diseases Drugs Revenue in 2023

3.5 Communicable Diseases Drugs Key Players Head office and Area Served

3.6 Key Players Communicable Diseases Drugs Product Solution and Service

3.7 Date of Enter into Communicable Diseases Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Communicable Diseases Drugs Breakdown Data by Type

4.1 Global Communicable Diseases Drugs Historic Market Size by Type (2019-2024)

4.2 Global Communicable Diseases Drugs Forecasted Market Size by Type (2025-2030)

5 Communicable Diseases Drugs Breakdown Data by Application

5.1 Global Communicable Diseases Drugs Historic Market Size by Application (2019-2024)

5.2 Global Communicable Diseases Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Communicable Diseases Drugs Market Size (2019-2030)

6.2 North America Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Communicable Diseases Drugs Market Size by Country (2019-2024)

6.4 North America Communicable Diseases Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Communicable Diseases Drugs Market Size (2019-2030)

7.2 Europe Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Communicable Diseases Drugs Market Size by Country (2019-2024)

7.4 Europe Communicable Diseases Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Communicable Diseases Drugs Market Size (2019-2030)

8.2 Asia-Pacific Communicable Diseases Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Communicable Diseases Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Communicable Diseases Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Communicable Diseases Drugs Market Size (2019-2030)

9.2 Latin America Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Communicable Diseases Drugs Market Size by Country (2019-2024)

9.4 Latin America Communicable Diseases Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Communicable Diseases Drugs Market Size (2019-2030)

10.2 Middle East & Africa Communicable Diseases Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Communicable Diseases Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Communicable Diseases Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Detail

11.1.2 Novartis Business Overview

11.1.3 Novartis Communicable Diseases Drugs Introduction

11.1.4 Novartis Revenue in Communicable Diseases Drugs Business (2019-2024)

11.1.5 Novartis Recent Development

11.2 Gilead

11.2.1 Gilead Company Detail

11.2.2 Gilead Business Overview

11.2.3 Gilead Communicable Diseases Drugs Introduction

11.2.4 Gilead Revenue in Communicable Diseases Drugs Business (2019-2024)

11.2.5 Gilead Recent Development

11.3 GSK

11.3.1 GSK Company Detail

11.3.2 GSK Business Overview

11.3.3 GSK Communicable Diseases Drugs Introduction

11.3.4 GSK Revenue in Communicable Diseases Drugs Business (2019-2024)

11.3.5 GSK Recent Development

11.4 Roche

11.4.1 Roche Company Detail

11.4.2 Roche Business Overview

11.4.3 Roche Communicable Diseases Drugs Introduction

11.4.4 Roche Revenue in Communicable Diseases Drugs Business (2019-2024)

11.4.5 Roche Recent Development

11.5 Merck

11.5.1 Merck Company Detail

11.5.2 Merck Business Overview

11.5.3 Merck Communicable Diseases Drugs Introduction

11.5.4 Merck Revenue in Communicable Diseases Drugs Business (2019-2024)

11.5.5 Merck Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Detail

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim Communicable Diseases Drugs Introduction

11.6.4 Boehringer Ingelheim Revenue in Communicable Diseases Drugs Business (2019-2024)

11.6.5 Boehringer Ingelheim Recent Development

11.7 Eli Lilly

11.7.1 Eli Lilly Company Detail

11.7.2 Eli Lilly Business Overview

11.7.3 Eli Lilly Communicable Diseases Drugs Introduction

11.7.4 Eli Lilly Revenue in Communicable Diseases Drugs Business (2019-2024)

11.7.5 Eli Lilly Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Detail

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Communicable Diseases Drugs Introduction

11.8.4 AstraZeneca Revenue in Communicable Diseases Drugs Business (2019-2024)

11.8.5 AstraZeneca Recent Development

11.9 J & J

11.9.1 J & J Company Detail

11.9.2 J & J Business Overview

11.9.3 J & J Communicable Diseases Drugs Introduction

11.9.4 J & J Revenue in Communicable Diseases Drugs Business (2019-2024)

11.9.5 J & J Recent Development

11.10 Teva

11.10.1 Teva Company Detail

11.10.2 Teva Business Overview

11.10.3 Teva Communicable Diseases Drugs Introduction

11.10.4 Teva Revenue in Communicable Diseases Drugs Business (2019-2024)

11.10.5 Teva Recent Development

11.11 AbbVie

11.11.1 AbbVie Company Detail

11.11.2 AbbVie Business Overview

11.11.3 AbbVie Communicable Diseases Drugs Introduction

11.11.4 AbbVie Revenue in Communicable Diseases Drugs Business (2019-2024)

11.11.5 AbbVie Recent Development

11.12 Bausch Health

11.12.1 Bausch Health Company Detail

11.12.2 Bausch Health Business Overview

11.12.3 Bausch Health Communicable Diseases Drugs Introduction

11.12.4 Bausch Health Revenue in Communicable Diseases Drugs Business (2019-2024)

11.12.5 Bausch Health Recent Development

11.13 Abbott

11.13.1 Abbott Company Detail

11.13.2 Abbott Business Overview

11.13.3 Abbott Communicable Diseases Drugs Introduction

11.13.4 Abbott Revenue in Communicable Diseases Drugs Business (2019-2024)

11.13.5 Abbott Recent Development

11.14 Sanofi

11.14.1 Sanofi Company Detail

11.14.2 Sanofi Business Overview

11.14.3 Sanofi Communicable Diseases Drugs Introduction

11.14.4 Sanofi Revenue in Communicable Diseases Drugs Business (2019-2024)

11.14.5 Sanofi Recent Development

11.15 Sun Pharma

11.15.1 Sun Pharma Company Detail

11.15.2 Sun Pharma Business Overview

11.15.3 Sun Pharma Communicable Diseases Drugs Introduction

11.15.4 Sun Pharma Revenue in Communicable Diseases Drugs Business (2019-2024)

11.15.5 Sun Pharma Recent Development

11.16 Endo

11.16.1 Endo Company Detail

11.16.2 Endo Business Overview

11.16.3 Endo Communicable Diseases Drugs Introduction

11.16.4 Endo Revenue in Communicable Diseases Drugs Business (2019-2024)

11.16.5 Endo Recent Development

11.17 Apotex

11.17.1 Apotex Company Detail

11.17.2 Apotex Business Overview

11.17.3 Apotex Communicable Diseases Drugs Introduction

11.17.4 Apotex Revenue in Communicable Diseases Drugs Business (2019-2024)

11.17.5 Apotex Recent Development

11.18 Amneal Pharma

11.18.1 Amneal Pharma Company Detail

11.18.2 Amneal Pharma Business Overview

11.18.3 Amneal Pharma Communicable Diseases Drugs Introduction

11.18.4 Amneal Pharma Revenue in Communicable Diseases Drugs Business (2019-2024)

11.18.5 Amneal Pharma Recent Development

11.19 Torrent Pharma

11.19.1 Torrent Pharma Company Detail

11.19.2 Torrent Pharma Business Overview

11.19.3 Torrent Pharma Communicable Diseases Drugs Introduction

11.19.4 Torrent Pharma Revenue in Communicable Diseases Drugs Business (2019-2024)

11.19.5 Torrent Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Novartis

Gilead

GSK

Roche

Merck

Boehringer Ingelheim

List of Tables

Table 1. Global Communicable Diseases Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of HIV

Table 3. Key Players of Influenza

Table 4. Key Players of TB

Table 5. Key Players of Malaria

Table 6. Key Players of Hepatitis

Table 7. Key Players of HPV

Table 8. Global Communicable Diseases Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Communicable Diseases Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Communicable Diseases Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 11. Global Communicable Diseases Drugs Market Share by Region (2019-2024)

Table 12. Global Communicable Diseases Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 13. Global Communicable Diseases Drugs Market Share by Region (2025-2030)

Table 14. Communicable Diseases Drugs Market Trends

Table 15. Communicable Diseases Drugs Market Drivers

Table 16. Communicable Diseases Drugs Market Challenges

Table 17. Communicable Diseases Drugs Market Restraints

Table 18. Global Communicable Diseases Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 19. Global Communicable Diseases Drugs Market Share by Players (2019-2024)

Table 20. Global Top Communicable Diseases Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Drugs as of 2023)

Table 21. Ranking of Global Top Communicable Diseases Drugs Companies by Revenue (US$ Million) in 2023

Table 22. Global 5 Largest Players Market Share by Communicable Diseases Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 23. Key Players Headquarters and Area Served

Table 24. Key Players Communicable Diseases Drugs Product Solution and Service

Table 25. Date of Enter into Communicable Diseases Drugs Market

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Communicable Diseases Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 28. Global Communicable Diseases Drugs Revenue Market Share by Type (2019-2024)

Table 29. Global Communicable Diseases Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 30. Global Communicable Diseases Drugs Revenue Market Share by Type (2025-2030)

Table 31. Global Communicable Diseases Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 32. Global Communicable Diseases Drugs Revenue Market Share by Application (2019-2024)

Table 33. Global Communicable Diseases Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 34. Global Communicable Diseases Drugs Revenue Market Share by Application (2025-2030)

Table 35. North America Communicable Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Communicable Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Communicable Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Communicable Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Europe Communicable Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 40. Europe Communicable Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 41. Asia-Pacific Communicable Diseases Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 42. Asia-Pacific Communicable Diseases Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 43. Asia-Pacific Communicable Diseases Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 44. Latin America Communicable Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Latin America Communicable Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 46. Latin America Communicable Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 47. Middle East & Africa Communicable Diseases Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Middle East & Africa Communicable Diseases Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Communicable Diseases Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 50. Novartis Company Detail

Table 51. Novartis Business Overview

Table 52. Novartis Communicable Diseases Drugs Product

Table 53. Novartis Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 54. Novartis Recent Development

Table 55. Gilead Company Detail

Table 56. Gilead Business Overview

Table 57. Gilead Communicable Diseases Drugs Product

Table 58. Gilead Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 59. Gilead Recent Development

Table 60. GSK Company Detail

Table 61. GSK Business Overview

Table 62. GSK Communicable Diseases Drugs Product

Table 63. GSK Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 64. GSK Recent Development

Table 65. Roche Company Detail

Table 66. Roche Business Overview

Table 67. Roche Communicable Diseases Drugs Product

Table 68. Roche Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 69. Roche Recent Development

Table 70. Merck Company Detail

Table 71. Merck Business Overview

Table 72. Merck Communicable Diseases Drugs Product

Table 73. Merck Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 74. Merck Recent Development

Table 75. Boehringer Ingelheim Company Detail

Table 76. Boehringer Ingelheim Business Overview

Table 77. Boehringer Ingelheim Communicable Diseases Drugs Product

Table 78. Boehringer Ingelheim Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 79. Boehringer Ingelheim Recent Development

Table 80. Eli Lilly Company Detail

Table 81. Eli Lilly Business Overview

Table 82. Eli Lilly Communicable Diseases Drugs Product

Table 83. Eli Lilly Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 84. Eli Lilly Recent Development

Table 85. AstraZeneca Company Detail

Table 86. AstraZeneca Business Overview

Table 87. AstraZeneca Communicable Diseases Drugs Product

Table 88. AstraZeneca Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 89. AstraZeneca Recent Development

Table 90. J & J Company Detail

Table 91. J & J Business Overview

Table 92. J & J Communicable Diseases Drugs Product

Table 93. J & J Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 94. J & J Recent Development

Table 95. Teva Company Detail

Table 96. Teva Business Overview

Table 97. Teva Communicable Diseases Drugs Product

Table 98. Teva Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 99. Teva Recent Development

Table 100. AbbVie Company Detail

Table 101. AbbVie Business Overview

Table 102. AbbVie Communicable Diseases Drugs Product

Table 103. AbbVie Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 104. AbbVie Recent Development

Table 105. Bausch Health Company Detail

Table 106. Bausch Health Business Overview

Table 107. Bausch Health Communicable Diseases Drugs Product

Table 108. Bausch Health Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 109. Bausch Health Recent Development

Table 110. Abbott Company Detail

Table 111. Abbott Business Overview

Table 112. Abbott Communicable Diseases Drugs Product

Table 113. Abbott Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 114. Abbott Recent Development

Table 115. Sanofi Company Detail

Table 116. Sanofi Business Overview

Table 117. Sanofi Communicable Diseases Drugs Product

Table 118. Sanofi Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 119. Sanofi Recent Development

Table 120. Sun Pharma Company Detail

Table 121. Sun Pharma Business Overview

Table 122. Sun Pharma Communicable Diseases Drugs Product

Table 123. Sun Pharma Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 124. Sun Pharma Recent Development

Table 125. Endo Company Detail

Table 126. Endo Business Overview

Table 127. Endo Communicable Diseases Drugs Product

Table 128. Endo Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 129. Endo Recent Development

Table 130. Apotex Company Detail

Table 131. Apotex Business Overview

Table 132. Apotex Communicable Diseases Drugs Product

Table 133. Apotex Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 134. Apotex Recent Development

Table 135. Amneal Pharma Company Detail

Table 136. Amneal Pharma Business Overview

Table 137. Amneal Pharma Communicable Diseases Drugs Product

Table 138. Amneal Pharma Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 139. Amneal Pharma Recent Development

Table 140. Torrent Pharma Company Detail

Table 141. Torrent Pharma Business Overview

Table 142. Torrent Pharma Communicable Diseases Drugs Product

Table 143. Torrent Pharma Revenue in Communicable Diseases Drugs Business (2019-2024) & (US$ Million)

Table 144. Torrent Pharma Recent Development

Table 145. Research Programs/Design for This Report

Table 146. Key Data Information from Secondary Sources

Table 147. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Communicable Diseases Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Communicable Diseases Drugs Market Share by Type: 2023 VS 2030

Figure 3. HIV Features

Figure 4. Influenza Features

Figure 5. TB Features

Figure 6. Malaria Features

Figure 7. Hepatitis Features

Figure 8. HPV Features

Figure 9. Global Communicable Diseases Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Communicable Diseases Drugs Market Share by Application: 2023 VS 2030

Figure 11. Hospital Case Studies

Figure 12. Clinic Case Studies

Figure 13. Other Case Studies

Figure 14. Communicable Diseases Drugs Report Years Considered

Figure 15. Global Communicable Diseases Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Communicable Diseases Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Communicable Diseases Drugs Market Share by Region: 2023 VS 2030

Figure 18. Global Communicable Diseases Drugs Market Share by Players in 2023

Figure 19. Global Top Communicable Diseases Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Drugs as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Communicable Diseases Drugs Revenue in 2023

Figure 21. North America Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Communicable Diseases Drugs Market Share by Country (2019-2030)

Figure 23. United States Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Communicable Diseases Drugs Market Share by Country (2019-2030)

Figure 27. Germany Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Communicable Diseases Drugs Market Share by Region (2019-2030)

Figure 35. China Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Communicable Diseases Drugs Market Share by Country (2019-2030)

Figure 43. Mexico Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Communicable Diseases Drugs Market Share by Country (2019-2030)

Figure 47. Turkey Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Communicable Diseases Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Novartis Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 50. Gilead Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 51. GSK Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 52. Roche Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 53. Merck Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 54. Boehringer Ingelheim Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 55. Eli Lilly Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 56. AstraZeneca Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 57. J & J Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 58. Teva Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 59. AbbVie Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 60. Bausch Health Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 61. Abbott Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 62. Sanofi Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 63. Sun Pharma Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 64. Endo Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 65. Apotex Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 66. Amneal Pharma Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 67. Torrent Pharma Revenue Growth Rate in Communicable Diseases Drugs Business (2019-2024)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions